Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Gross-to-Net government & payer rebate accruals by Year
Gross-to-Net (GTN) government & payer rebate accruals — Ending balance ($M) ($M)
Vertex Pharmaceuticals Gross-to-Net government & payer rebate accruals: $1,778M in FY2025, up 10.6% from a year earlier. That is the highest of the 13 years on record here.
Where the FY2025 figure comes from
“|| Balance at December 31, 2025 | $ 1,777.6”
Source: Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-K MD&A (Critical Accounting Policies — Gross-to-Net Rebate Rollforward).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up gross-to-Net government & payer rebate accruals
- GTN rebate accruals — Beginning balance ($M)1,607 · FY2025
- GTN rebate accruals — Provision for current year product sales ($M)3,780 · FY2025
- GTN rebate accruals — Adjustments relating to prior year product sales ($M)-90.4 · FY2025
- GTN rebate accruals — Credits and payments made ($M)-3,520 · FY2025
- Total GTN sales deduction reserves (including chargebacks & returns, FY2013–FY2017) — Ending balance ($M)123 · FY2017
Cite this data
StockData. (2026). Vertex Pharmaceuticals Gross-to-Net government & payer rebate accruals ($M), annual FY2013–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/gtn-end-bal
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.